Stockscreener 앱 받기
1.10
139.03%
0.6398
시간 외 거래:
1.04
-0.06
-5.45%
전일 마감가:
$0.4602
열려 있는:
$0.8831
하루 거래량:
135.95M
Relative Volume:
62.76
시가총액:
$3.39M
수익:
-
순이익/손실:
$-33.44M
주가수익비율:
-0.0686
EPS:
-16.0242
순현금흐름:
$-28.30M
1주 성능:
+96.39%
1개월 성능:
+39.06%
6개월 성능:
-28.10%
1년 성능:
-72.50%
1일 변동 폭
$0.6576
$1.25
1주일 범위
$0.4133
$1.25
52주 변동 폭
$0.4133
$10.79
Nucana Plc Adr Stock (NCNA) Company Profile
NCNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NCNA
Nucana Plc Adr
|
1.10 | 3.39M | 0 | -33.44M | -28.30M | -16.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.50 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Nucana Plc Adr Stock (NCNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-03 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-10-22 | 개시 | Truist | Buy |
| 2020-07-24 | 개시 | Oppenheimer | Outperform |
| 2019-08-19 | 개시 | H.C. Wainwright | Buy |
| 2018-10-19 | 개시 | Piper Jaffray | Overweight |
| 2017-10-23 | 개시 | Citigroup | Buy |
| 2017-10-23 | 개시 | Jefferies | Buy |
| 2017-10-23 | 개시 | William Blair | Outperform |
모두보기
Nucana Plc Adr 주식(NCNA)의 최신 뉴스
New Outlook On NuCana plc ADR - Stocksregister
NCNA’s Stock Journey: What Investors Need to Know About NuCana plc ADR’s Performance - investchronicle.com
Do investors need to be concerned about Cadiz Inc (CDZI)? - uspostnews.com
Natera Inc (NTRA) deserves closer scrutiny - uspostnews.com
Weave Communications Inc (WEAV) produces promising results - uspostnews.com
Investing in NuCana plc ADR (NCNA) might be an excellent idea, but the stock is currently overvalued/undervalued - uspostnews.com
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season? - Nasdaq
Post-Trade Analysis: NuCana plc ADR (NCNA) Slides -26.97, Closing at 0.65 - DWinneX
Closing Bell Recap: Yxt.Com Group Holding Ltd. ADR (YXT) Ends at 0.56, Reflecting a -14.42 Downturn - DWinneX
In the Green: Gogoro Inc (GGR) Closes at 0.26, Up/Down 0.08 from Previous Day - DWinneX
Daily Market Movement: Tivic Health Systems Inc (TIVC) Sees a 1.88 Increase, Closing at 7.04 - DWinneX
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks - Barchart.com
Stock Update - Investorsobserver
NuCana Reports Strong Phase 2 Data: 75% Disease Control in Melanoma Trial, Lower Q3 Loss - StockTitan
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study - Yahoo Finance
Oppenheimer slashes NuCana stock target, remains Outperform on optimism for upcoming trials - Investing.com
NuCana Ends Phase 2 Cancer Study, Focuses on Promising Treatments - TipRanks
NuCana shares receive $150 stock PT at Oppenheimer on upbeat trial prospects - Investing.com
NuCana plc Announces Reverse ADS Split - TipRanks
NuCana: Potential Turnaround In 2024 But Risky - Seeking Alpha
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
Will NuCana Continue to Surge Higher? - Nasdaq
NCNA Stock Price and Chart — NASDAQ:NCNA - TradingView
NuCana PLC Stock Price Today | NASDAQ: NCNA Live - Investing.com
Nucana Plc Adr (NCNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):